Please use this identifier to cite or link to this item:
Title: Can we predict and prevent specific sites of metastases in breast cancer patients?
Author: Salvador, Fernando
Bellmunt, Anna
Gomis i Cabré, Roger
Keywords: Pronòstic mèdic
Biologia molecular
Càncer de mama
Molecular biology
Breast cancer
Issue Date: 18-May-2016
Publisher: Future Medicine
Abstract: Despite improvements in breast cancer therapies, cancer cells frequently spread to distant organs years or decades after primary tumor surgery and adjuvant treatment. This expansion, known as metastasis, can bring about fatal consequences. Traditionally, the risk of metastasis has been predicted by prognostic factors such as tumor size, axillary lymph node status and histological grade. More recently, genomic tests have also been used for this purpose. The presence of ER, PR and ERBB2 gene amplification are currently key markers in the characterization of breast tumor type that drive the selection of specific therapies. ER-positive tumors are more prone to metastasize into the bone, whereas ER-negative tumors preferentially spread to visceral organs such as lung, liver and brain. However, the reliability of these markers is limited. In this regard, substantial efforts have been made to find new markers that predict the most probable target organ of metastasis, with the aim to improve diagnosis and develop organ-specific treatments for breast cancer metastatic patients.
Note: Versió postrprint del document publicat a:
It is part of: Breast Cancer Management, 2016, vol. 5, num. 2, p. 43-46
Related resource:
ISSN: 1758-1923
Appears in Collections:Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))

Files in This Item:
File Description SizeFormat 
2953.pdf6.09 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.